Open an account

Moleculin Biotech

MBRX · NASDAQ

$6.19+$5.93 (+2235.85%)TodayMarket closed ·
Prev close $0.265

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Employees
17
Headquarters
Houston, Texas
Listed
Jun 2, 2016
Sector
Health Care
Industry
Biotechnology
Website
moleculin.com

MBRX key statistics

Market cap
110.77M
Price-earnings ratio
0.03
Dividend yield
—
Average volume
1.15M
Volume
132.46K
Open price
$5.74
High today
$6.40
Low today
$5.24
52 Week high
$15.75
52 Week low
$0.1614

Moleculin Biotech (MBRX) at a glance

Moleculin Biotech (MBRX) last traded at $6.19, with a market cap of 110.77M and a price-to-earnings ratio of 0.03.

Today the stock has traded between $5.24 and $6.40. The current price is 18.1% above the day's low and 3.3% below its high.

Volume so far is 132.46K shares, below the average of 1.15M shares a day.

Over the past year Moleculin Biotech has ranged from $0.1614 to $15.75, and now sits 39% of the way up that range.

Moleculin Biotech met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.40 per share against an estimate of -$1.58.

The average analyst price target is $12.24, 97.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $12.24
Low
$2.02
Now
$6.19
High
$32.55

MBRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 130.8% on average.

  1. Q3 FY24: reported -$71.25 per share against an estimate of -$62.22
  2. Q4 FY24: reported -$9.32 per share against an estimate of -$32.72
  3. Q1 FY25: reported -$17.25 per share against an estimate of -$14.15
  4. Q2 FY25: reported -$12.25 per share against an estimate of -$9.26
  5. Q3 FY25: reported -$17.00 per share against an estimate of -$4.97
  6. Q4 FY25: reported $13.04 per share against an estimate of -$6.24
  7. Q1 FY26: reported -$3.54 per share against an estimate of -$1.70
  8. Q2 FY26: reported -$1.40 per share against an estimate of -$1.58

MBRX news

  • Avi Kapoor

    Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Vandana Singh

    Moleculin Biotech Stock Is Sinking Friday: What's Going On?

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Vandana Singh

    Why is Moleculin Stock Falling Today?

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia

  • Press releaseGlobe Newswire

    Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment

Similar companies

Companies in the same industry as Moleculin Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.